Johan Richter
71 – 80 of 108
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Neonatal bone marrow transplantation without prior conditioning rapidly reverses osteopetrosis in oc/oc mice despite only minimal donor cell engraftment
(
- Contribution to journal › Published meeting abstract
-
Mark
Low-dose busulphan conditioning and neonatal stem cell transplantation preserves vision and restores hematopoiesis in severe murine osteopetrosis.
(
- Contribution to journal › Article
-
Mark
Prospects for gene therapy of osteopetrosis.
(
- Contribution to journal › Article
- 2008
-
Mark
Neonatal hematopoietic stem cell transplantation following low-dose busulphan conditioning reverses osteopetrosis and preserves vision in oc/oc mice
2008) 16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy In Human Gene Therapy 19(10). p.1183-1184(
- Contribution to journal › Published meeting abstract
-
Mark
Human Primary Mensenchymal Stromal Progenitor Cells Are Highly Enriched in Both, the CD271(+)/CD146(+) and CD271(+)/CD146(-) Bone Marrow Population with the Latter Acquiring CD146 Expression upon Culture in-Vitro.
(
- Contribution to journal › Published meeting abstract
-
Mark
RPS19 Deficiency Leads to Reduced Proliferation and Increased Apoptosis but Does Not Affect Terminal Erythroid Differentiation in a Cell Line Model of Diamond-Blackfan Anemia
(
- Contribution to journal › Article
-
Mark
Towards a better understanding and new therapeutics of osteopetrosis.
(
- Contribution to journal › Scientific review
-
Mark
Gene therapy of Diamond Blackfan anemia CD34(+) cells leads to improved erythroid development and engraftment following transplantation.
(
- Contribution to journal › Article
-
Mark
Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease.
2008) p.1189-1190(
- Contribution to conference › Poster
- 2007
-
Mark
Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome.
(
- Contribution to journal › Article